C Difficile Vaccine Candidate Misses Study Primary End Point

The journal Clinical Infectious Diseases recently published results from an extensive, observer-blinded, CLOVER phase 3 clinical trial that found a Clostridioides difficile vaccine candidate was safe, well tolerated, and reduced the severity of C difficile infection (CDI).

However, this vaccine did not reduce the incidence of CDI in at-risk adults.

Although the primary endpoint of this study was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden, wrote these researchers on August 24, 2024.

The U.S. CDC says CDI causes substantial mortality and healthcare burden. In 2022, the incidence rate of CDI increased with age, and rates were higher in women.

As of August 27, 2024, no C difficile infection protection vaccines are available.